(DHR) Danaher - Overview
Stock: Bioprocessing, Diagnostics, Instruments, Consumables, Software
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.63% |
| Yield on Cost 5y | 0.63% |
| Yield CAGR 5y | 11.10% |
| Payout Consistency | 90.8% |
| Payout Ratio | 12.9% |
| Risk 5d forecast | |
|---|---|
| Volatility | 27.5% |
| Relative Tail Risk | -7.83% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.15 |
| Alpha | -12.20 |
| Character TTM | |
|---|---|
| Beta | 0.941 |
| Beta Downside | 0.906 |
| Drawdowns 3y | |
|---|---|
| Max DD | 37.57% |
| CAGR/Max DD | -0.04 |
Description: DHR Danaher January 27, 2026
Danaher Corp. (NYSE:DHR) is a diversified industrial and life-sciences conglomerate that designs, manufactures, and markets professional, medical, research, and industrial products worldwide, with major operations in the United States and China. The firm is organized into three operating segments-Biotechnology, Life Sciences, and Diagnostics-each delivering specialized hardware, consumables, and services that support therapeutic development, laboratory research, and clinical testing.
In its most recent fiscal year (2023), Danaher reported revenue of $33.5 billion, an operating margin of 21 percent, and diluted earnings per share of $12.44, reflecting steady growth despite a volatile macro environment. The Biotechnology segment, which benefits from the accelerating adoption of cell-therapy and single-use bioprocessing, grew 9 percent YoY, while the Life Sciences segment-driven by demand for mass spectrometry, genomics, and automation-expanded 11 percent. The Diagnostics segment, buoyed by an aging population and higher hospital testing volumes, posted a 7 percent increase in sales. Key economic drivers include a projected 4 percent annual rise in U.S. healthcare spending and a robust pipeline of biologics that fuels demand for Danaher’s bioprocessing solutions.
Assuming current market conditions persist, Danaher’s diversified revenue base and high-margin product mix position it to capture continued upside in the expanding life-sciences and diagnostics markets; however, any slowdown in biotech financing or supply-chain disruptions could materially affect segment performance.
For a deeper quantitative assessment, you might explore ValueRay’s detailed valuation models.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 3.61b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -0.53 > 1.0 |
| NWC/Revenue: 24.21% < 20% (prev 11.30%; Δ 12.91% < -1%) |
| CFO/TA 0.08 > 3% & CFO 6.42b > Net Income 3.61b |
| Net Debt (13.80b) to EBITDA (6.95b): 1.99 < 3 |
| Current Ratio: 1.87 > 1.5 & < 3 |
| Outstanding Shares: last quarter (711.0m) vs 12m ago -3.55% < -2% |
| Gross Margin: 60.93% > 18% (prev 0.60%; Δ 6034 % > 0.5%) |
| Asset Turnover: 30.52% > 50% (prev 30.79%; Δ -0.27% > 0%) |
| Interest Coverage Ratio: 16.97 > 6 (EBITDA TTM 6.95b / Interest Expense TTM 265.0m) |
Altman Z'' 4.26
| A: 0.07 (Total Current Assets 12.76b - Total Current Liabilities 6.81b) / Total Assets 83.46b |
| B: 0.56 (Retained Earnings 46.89b / Total Assets 83.46b) |
| C: 0.06 (EBIT TTM 4.50b / Avg Total Assets 80.50b) |
| D: 1.51 (Book Value of Equity 46.69b / Total Liabilities 30.93b) |
| Altman-Z'' Score: 4.26 = AA |
Beneish M -3.18
| DSRI: 0.87 (Receivables 3.91b/4.39b, Revenue 24.57b/23.88b) |
| GMI: 0.98 (GM 60.93% / 59.50%) |
| AQI: 0.98 (AQ_t 0.78 / AQ_t-1 0.80) |
| SGI: 1.03 (Revenue 24.57b / 23.88b) |
| TATA: -0.03 (NI 3.61b - CFO 6.42b) / TA 83.46b) |
| Beneish M-Score: -3.18 (Cap -4..+1) = AA |
What is the price of DHR shares?
Over the past week, the price has changed by -1.04%, over one month by -8.44%, over three months by +2.96% and over the past year by +3.79%.
Is DHR a buy, sell or hold?
- StrongBuy: 19
- Buy: 4
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the DHR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 265.2 | 22.4% |
| Analysts Target Price | 265.2 | 22.4% |
| ValueRay Target Price | 218.4 | 0.8% |
DHR Fundamental Data Overview January 31, 2026
P/E Forward = 25.7732
P/S = 6.3507
P/B = 2.9552
P/EG = 2.0429
Revenue TTM = 24.57b USD
EBIT TTM = 4.50b USD
EBITDA TTM = 6.95b USD
Long Term Debt = 18.42b USD (from longTermDebt, last quarter)
Short Term Debt = 2.00m USD (from shortTermDebt, last quarter)
Debt = 18.42b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 13.80b USD (from netDebt column, last quarter)
Enterprise Value = 169.83b USD (156.02b + Debt 18.42b - CCE 4.62b)
Interest Coverage Ratio = 16.97 (Ebit TTM 4.50b / Interest Expense TTM 265.0m)
EV/FCF = 32.29x (Enterprise Value 169.83b / FCF TTM 5.26b)
FCF Yield = 3.10% (FCF TTM 5.26b / Enterprise Value 169.83b)
FCF Margin = 21.41% (FCF TTM 5.26b / Revenue TTM 24.57b)
Net Margin = 14.71% (Net Income TTM 3.61b / Revenue TTM 24.57b)
Gross Margin = 60.93% ((Revenue TTM 24.57b - Cost of Revenue TTM 9.60b) / Revenue TTM)
Gross Margin QoQ = 58.00% (prev 58.20%)
Tobins Q-Ratio = 2.03 (Enterprise Value 169.83b / Total Assets 83.46b)
Interest Expense / Debt = 0.30% (Interest Expense 55.0m / Debt 18.42b)
Taxrate = 12.82% (176.0m / 1.37b)
NOPAT = 3.92b (EBIT 4.50b * (1 - 12.82%))
Current Ratio = 1.87 (Total Current Assets 12.76b / Total Current Liabilities 6.81b)
Debt / Equity = 0.35 (Debt 18.42b / totalStockholderEquity, last quarter 52.53b)
Debt / EBITDA = 1.99 (Net Debt 13.80b / EBITDA 6.95b)
Debt / FCF = 2.62 (Net Debt 13.80b / FCF TTM 5.26b)
Total Stockholder Equity = 51.70b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.49% (Net Income 3.61b / Total Assets 83.46b)
RoE = 6.99% (Net Income TTM 3.61b / Total Stockholder Equity 51.70b)
RoCE = 6.42% (EBIT 4.50b / Capital Employed (Equity 51.70b + L.T.Debt 18.42b))
RoIC = 5.74% (NOPAT 3.92b / Invested Capital 68.31b)
WACC = 8.42% (E(156.02b)/V(174.44b) * Re(9.38%) + D(18.42b)/V(174.44b) * Rd(0.30%) * (1-Tc(0.13)))
Discount Rate = 9.38% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.38%
[DCF Debug] Terminal Value 75.75% ; FCFF base≈5.27b ; Y1≈5.01b ; Y5≈4.78b
Fair Price DCF = 91.69 (EV 78.62b - Net Debt 13.80b = Equity 64.81b / Shares 706.9m; r=8.42% [WACC]; 5y FCF grow -6.55% → 2.90% )
EPS Correlation: -71.61 | EPS CAGR: -5.53% | SUE: 0.52 | # QB: 0
Revenue Correlation: -60.68 | Revenue CAGR: -3.08% | SUE: 0.09 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.95 | Chg30d=-0.058 | Revisions Net=-1 | Analysts=21
EPS current Year (2026-12-31): EPS=8.42 | Chg30d=-0.004 | Revisions Net=+2 | Growth EPS=+7.9% | Growth Revenue=+4.3%
EPS next Year (2027-12-31): EPS=9.15 | Chg30d=-0.155 | Revisions Net=-3 | Growth EPS=+8.7% | Growth Revenue=+5.7%